ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SKB103

A development code. Also written as “SKB103 monotherapy” and “SKB103 for injection monotherapy”.

Its studies are mostly in Breast Neoplasms, led by Sichuan Kelun Pharmaceutical.

Furthest: phase 2, since Mar 4, 20262 company-led studies, 2 open or runningNext primary completion: Dec 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical22 open or runningphase 2since Mar 4, 2026Mar 4, 2026Dec 31, 2029phase 2 · NCT07774624

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 4, 2026First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07459998 · 277 planned · China
  2. Aug 12, 2026Phase 2 study in Breast NeoplasmsNCT07774624 · 140 planned

Ahead

  1. Dec 31, 2029Primary completion: phase 2 study in Breast NeoplasmsNCT07774624
  2. Dec 31, 2029Primary completion: phase 2 study in Advanced Solid TumorsNCT07459998

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07774624Breast Neoplasms2Not yet recruitingDec 31, 2029140
NCT07459998Advanced Solid Tumors · China2RecruitingDec 31, 2029277

How it is read

Names in the registry

  • “SKB103 monotherapy”, 1 entry
  • “SKB103 for injection monotherapy”, 1 entry

Codes read as this program: SKB103.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.